SynthesisYonsei medical journal2026
Medical Expulsive Therapy after Extracorporeal Shock Wave Lithotripsy: A Systematic Review and Network Meta-Analysis.
Synthesis in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMedical expulsive therapy (MET) after extracorporeal shock wave lithotripsy (ESWL) remains a subject of debate. We aimed to evaluate the comparative efficacy and safety of various pharmacological interventions using a network meta-analysis (NMA) of 21 randomized controlled trials (RCTs). MATERIALS AND
methodsA systematic search of PubMed, EMBASE, and the Cochrane Library was conducted through 2024 (Open Science Framework registered). We included only purely pharmacological RCTs, strictly excluding non-randomized studies and device-assisted trials. A Bayesian NMA was performed to estimate odds ratios and the surface under the cumulative ranking curve (SUCRA) for stone-free rates and complications.
resultsTwenty-one RCTs involving 3262 patients were analyzed. The tamsulosin-tadalafil combination was identified as the most effective strategy (SUCRA: 93.8%), followed by tamsulosin-corticosteroid (78.2%) and boron supplementation (67.9%). Notably, while silodosin is often superior for single intact stones, it ranked relatively low in the post-ESWL setting (SUCRA: 20.9%). All agents showed acceptable safety profiles without significant serious adverse events compared to controls.
conclusionThe tamsulosin-tadalafil combination represents the optimal pharmacological adjunct to ESWL. Our findings suggest that effective post-ESWL MET requires a broad therapeutic approach targeting multi-segmental ureteral relaxation and inflammation to clear fragment "showers," distinguishing it from the management of solitary ureteral stones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.